<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468481</url>
  </required_header>
  <id_info>
    <org_study_id>91523</org_study_id>
    <secondary_id>310662</secondary_id>
    <nct_id>NCT00468481</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study for an Oral Contraceptive Containing Folate</brief_title>
  <official_title>Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the study drug is safe and effective
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acronym is used in result section: suspected/diagnosed (susp/diag)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Red Blood Cell (RBC) Folate Level at 24 Weeks</measure>
    <time_frame>Week 24</time_frame>
    <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Folate Level at 24 Weeks</measure>
    <time_frame>Week 24</time_frame>
    <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Neural Tube Defect (NTD) Risk Reduction at Week 24</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4</measure>
    <time_frame>baseline and up to week 4</time_frame>
    <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8</measure>
    <time_frame>baseline and up to week 8</time_frame>
    <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12</measure>
    <time_frame>baseline and up to week 12</time_frame>
    <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16</measure>
    <time_frame>baseline and up to week 16</time_frame>
    <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20</measure>
    <time_frame>baseline and up to week 20</time_frame>
    <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Folate Levels at Week 4</measure>
    <time_frame>baseline and up to week 4</time_frame>
    <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Folate Levels at Week 8</measure>
    <time_frame>baseline and up to week 8</time_frame>
    <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Folate Levels at Week 12</measure>
    <time_frame>baseline and up to week 12</time_frame>
    <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Folate Levels at Week 16</measure>
    <time_frame>baseline and up to week 16</time_frame>
    <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Folate Levels at Week 20</measure>
    <time_frame>baseline and up to week 20</time_frame>
    <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Homocysteine Levels at Week 4</measure>
    <time_frame>baseline and up to week 4</time_frame>
    <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Homocysteine Levels at Week 8</measure>
    <time_frame>baseline and up to week 8</time_frame>
    <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Homocysteine Levels at Week 12</measure>
    <time_frame>baseline and up to week 12</time_frame>
    <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Homocysteine Levels at Week 16</measure>
    <time_frame>baseline and up to week 16</time_frame>
    <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Homocysteine Levels at Week 20</measure>
    <time_frame>baseline and up to week 20</time_frame>
    <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Plasma Homocysteine Levels at Week 24</measure>
    <time_frame>baseline and up to week 24</time_frame>
    <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Neural Tube Defects</condition>
  <condition>Contraception</condition>
  <condition>Oral Contraceptives (OC)</condition>
  <arm_group>
    <arm_group_label>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drospirenone (DRSP)/Ethinylestradiol (EE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drospirenone/Ethinylestradiol/Methyltetrahydrofolate</intervention_name>
    <description>0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)</description>
    <arm_group_label>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drospirenone/Ethinylestradiol (Yaz)</intervention_name>
    <description>0.020 mg ethinylestradiol with 3.0 mg drospirenone</description>
    <arm_group_label>Drospirenone (DRSP)/Ethinylestradiol (EE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Healthy women between 18 and 40 requesting oral contraception

        Exclusion Criteria:

        - The use of steroidal oral contraceptives, or any drug that could alter Oral Contraception
        metabolism will be prohibited during the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center, Inc.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AAIPharma, Inc.</name>
      <address>
        <city>Morrisville</city>
        <state>North Carolina</state>
        <zip>27560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Gynecologic Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthWest Kinetics</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Bart S Sr, Marr J, Diefenbach K, Trummer D, Sampson-Landers C. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study. Contraception. 2012 Jan;85(1):42-50. doi: 10.1016/j.contraception.2011.05.013. Epub 2011 Jul 13.</citation>
    <PMID>22067790</PMID>
  </results_reference>
  <results_reference>
    <citation>Casta√±o PM, Aydemir A, Sampson-Landers C, Lynen R. The folate status of reproductive-aged women in a randomised trial of a folate-fortified oral contraceptive: dietary and blood assessments. Public Health Nutr. 2014 Jun;17(6):1375-83. doi: 10.1017/S1368980013000864. Epub 2013 Mar 27.</citation>
    <PMID>23534865</PMID>
  </results_reference>
  <results_reference>
    <citation>Taylor TN, Farkouh RA, Graham JB, Colligs A, Lindemann M, Lynen R, Candrilli SD. Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States. Am J Obstet Gynecol. 2011 Nov;205(5):460.e1-8. doi: 10.1016/j.ajog.2011.06.048. Epub 2011 Jun 21.</citation>
    <PMID>21903192</PMID>
  </results_reference>
  <results_reference>
    <citation>Campone M, Berton-Rigaud D, Joly-Lobbedez F, Baurain JF, Rolland F, Stenzl A, Fabbro M, van Dijk M, Pinkert J, Schmelter T, de Bont N, Pautier P. A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. Oncologist. 2013;18(11):1190-1. doi: 10.1634/theoncologist.2013-0061. Epub 2013 Oct 8.</citation>
    <PMID>24105751</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2007</study_first_posted>
  <results_first_submitted>January 4, 2011</results_first_submitted>
  <results_first_submitted_qc>January 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2011</results_first_posted>
  <disposition_first_submitted>November 19, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 19, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 23, 2009</disposition_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy women requesting contraception</keyword>
  <keyword>Folic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neural Tube Defects</mesh_term>
    <mesh_term>Spinal Dysraphism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>572 subjects screened; 187 subjects screen failed; 385 subjects randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
          <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
          <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="291">6 of these randomized subjects did not take any study medication</participants>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Treated</title>
              <participants_list>
                <participants group_id="P1" count="285"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>susp/diag malignant/premalignant disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Egg Donor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of area</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
          <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
          <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="285"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="379"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="B2" value="24.6" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="B3" value="24.7" lower_limit="18" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Red Blood Cell (RBC) Folate Level at 24 Weeks</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>Week 24</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cell (RBC) Folate Level at 24 Weeks</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1406.91" lower_limit="1354.13" upper_limit="1459.68"/>
                    <measurement group_id="O2" value="1022.21" lower_limit="934.6" upper_limit="1109.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the difference between DRSP/EE/MTHF and Yaz treatment groups in the RBC folate levels at week 24 was 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of Covariance (ANCOVA) with treatment as factor and Baseline (RBC folate) as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>384.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>282.42</ci_lower_limit>
            <ci_upper_limit>486.98</ci_upper_limit>
            <estimate_desc>Difference = DRSP/EE/MTHF - YAZ</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Folate Level at 24 Weeks</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>Week 24</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Folate Level at 24 Weeks</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.55" lower_limit="58.13" upper_limit="62.97"/>
                    <measurement group_id="O2" value="41.67" lower_limit="37.50" upper_limit="45.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that the difference between DRSP/EE/MTHF and Yaz treatment groups in the plasma folate levels at week 24 was 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of Covariance (ANCOVA) with treatment as factor and Baseline (plasma folate) as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>14.04</ci_lower_limit>
            <ci_upper_limit>23.70</ci_upper_limit>
            <estimate_desc>Difference =DRSP/EE/MTHF - YAZ</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Neural Tube Defect (NTD) Risk Reduction at Week 24</title>
        <description>The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Neural Tube Defect (NTD) Risk Reduction at Week 24</title>
          <description>The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>per 1000 birth</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.41"/>
                    <measurement group_id="O2" value="-0.03" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>baseline and up to week 4</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.9" spread="207.28"/>
                    <measurement group_id="O2" value="-37.6" spread="195.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>baseline and up to week 8</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310.3" spread="231.47"/>
                    <measurement group_id="O2" value="68.2" spread="155.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>baseline and up to week 12</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.8" spread="243.88"/>
                    <measurement group_id="O2" value="86.5" spread="177.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>baseline and up to week 16</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448.9" spread="280.37"/>
                    <measurement group_id="O2" value="68.0" spread="186.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>baseline and up to week 20</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="452.7" spread="284.64"/>
                    <measurement group_id="O2" value="64.6" spread="194.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Folate Levels at Week 4</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>baseline and up to week 4</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Folate Levels at Week 4</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="22.07"/>
                    <measurement group_id="O2" value="0.6" spread="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Folate Levels at Week 8</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>baseline and up to week 8</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Folate Levels at Week 8</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>¬µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="19.17"/>
                    <measurement group_id="O2" value="2.2" spread="14.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Folate Levels at Week 12</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>baseline and up to week 12</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Folate Levels at Week 12</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="20.1"/>
                    <measurement group_id="O2" value="0.3" spread="15.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Folate Levels at Week 16</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>baseline and up to week 16</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Folate Levels at Week 16</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="12.43"/>
                    <measurement group_id="O2" value="2.4" spread="16.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Folate Levels at Week 20</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>baseline and up to week 20</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Folate Levels at Week 20</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="22.71"/>
                    <measurement group_id="O2" value="-1.6" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 4</title>
        <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
        <time_frame>baseline and up to week 4</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 4</title>
          <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>¬µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.04"/>
                    <measurement group_id="O2" value="0" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 8</title>
        <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
        <time_frame>baseline and up to week 8</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 8</title>
          <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>¬µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.9"/>
                    <measurement group_id="O2" value="0" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 12</title>
        <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
        <time_frame>baseline and up to week 12</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 12</title>
          <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>¬µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.07"/>
                    <measurement group_id="O2" value="0" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 16</title>
        <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
        <time_frame>baseline and up to week 16</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 16</title>
          <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>¬µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.02"/>
                    <measurement group_id="O2" value="-0.1" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 20</title>
        <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
        <time_frame>baseline and up to week 20</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 20</title>
          <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>¬µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.07"/>
                    <measurement group_id="O2" value="-0.2" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 24</title>
        <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
        <time_frame>baseline and up to week 24</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Plasma Homocysteine Levels at Week 24</title>
          <description>Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>¬µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.93"/>
                    <measurement group_id="O2" value="0.1" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>at baseline (week 0)</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="910.9" spread="276.05"/>
                    <measurement group_id="O2" value="915.1" spread="233.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>at baseline (week 0)</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1122.8" spread="504.7"/>
                    <measurement group_id="O2" value="1345.0" spread="301.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 4</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1007.1" spread="329.67"/>
                    <measurement group_id="O2" value="889.5" spread="262.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 4</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1175.7" spread="428.58"/>
                    <measurement group_id="O2" value="1256.1" spread="190.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 8</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1184.8" spread="338.5"/>
                    <measurement group_id="O2" value="970.4" spread="252.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 8</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1412.7" spread="436.69"/>
                    <measurement group_id="O2" value="1407.6" spread="290.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 12</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1308.9" spread="374.61"/>
                    <measurement group_id="O2" value="1025.2" spread="287.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 12</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1469.8" spread="454.62"/>
                    <measurement group_id="O2" value="1378.4" spread="375.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 16</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1365.2" spread="403.12"/>
                    <measurement group_id="O2" value="967.6" spread="255.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 16</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1460.5" spread="472.23"/>
                    <measurement group_id="O2" value="1454.7" spread="355.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 20</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1419.8" spread="558.1"/>
                    <measurement group_id="O2" value="981.3" spread="252.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 20</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1486.6" spread="462.8"/>
                    <measurement group_id="O2" value="1435.9" spread="319.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 24</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1355.3" spread="364.85"/>
                    <measurement group_id="O2" value="949.2" spread="256.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24</title>
        <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
        <time_frame>up to week 24</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24</title>
          <description>RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1500.3" spread="525.71"/>
                    <measurement group_id="O2" value="1316.1" spread="237.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>at baseline (week 0)</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="16.2"/>
                    <measurement group_id="O2" value="41.5" spread="15.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>at baseline (week 0)</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.3" spread="18.45"/>
                    <measurement group_id="O2" value="47.1" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 4</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="24.83"/>
                    <measurement group_id="O2" value="43.1" spread="17.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 4</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.4" spread="27.56"/>
                    <measurement group_id="O2" value="45.9" spread="21.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 8</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" spread="22.41"/>
                    <measurement group_id="O2" value="41.8" spread="14.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 8</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" spread="26.60"/>
                    <measurement group_id="O2" value="54.1" spread="30.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 12</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="20.39"/>
                    <measurement group_id="O2" value="42.3" spread="17.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 12</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.4" spread="23.69"/>
                    <measurement group_id="O2" value="46.4" spread="17.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 16</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="18.89"/>
                    <measurement group_id="O2" value="43.2" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 16</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="26.38"/>
                    <measurement group_id="O2" value="51.8" spread="21.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 20</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" spread="21.11"/>
                    <measurement group_id="O2" value="39.7" spread="16.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 20</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" spread="24.16"/>
                    <measurement group_id="O2" value="45.9" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 24</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="17.73"/>
                    <measurement group_id="O2" value="39.8" spread="18.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24</title>
        <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
        <time_frame>up to week 24</time_frame>
        <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
            <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24</title>
          <description>Folate concentrations in plasma were determined by an appropriately validated microbiological assay.</description>
          <population>Analysis was based on Per Protocol Set (PPS) defined as all subjects who had no major protocol deviations and completed 24 weeks of treatment with valid data for one of the co-primary efficacy variables at baseline and week 24.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="22.61"/>
                    <measurement group_id="O2" value="43.7" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)</title>
          <description>1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Drospirenone (DRSP)/Ethinylestradiol (EE)</title>
          <description>1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Human papilloma virus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="285"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="285"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholinesterase decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="285"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Prothrombin level decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Human papilloma virus test positive</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="285"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="285"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

